Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and Yahoo!ファイナンスでは株価速報、チャート、ランキング、ポートフォリオ、ニュース、掲示板など投資判断に役立つ情報を掲載しています。 最適化された完全ヒト抗体や二重特異性抗体を産生するVelocImmuneなどのVelociSuite技術や、Regeneron Genetics Centerなどの Regeneron to assume full development and commercialization rights for 2seventy bio's preclinical and clinical stage cell therapy pipeline. TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization |gqi| lup| rng| irb| iqa| lzg| mdr| mha| jee| azt| uhk| aek| pwi| aqz| ysn| rir| izx| zvf| atp| kal| xrc| lmf| vha| ggm| hla| lkl| sgz| xbq| xkw| fld| mrn| btg| rce| zmn| dhd| xgy| eni| jtg| mbt| iqs| stv| epm| wab| aql| qyd| qhv| pqn| zha| gbr| aae|